Introduction
HELLP syndrome, bone marrow transplantation, drug (mitomycin, cyclosporin A, ticlopidine) therapy, and Haemolytic-uraemic syndrome (HUS) and thrombotic cancer, and have been variously referred to as TTP, thrombocytopenic purpura ( TTP) are two clinically HUS, TTP/HUS, TTP-like disease or secondary TTP. similar disorders characterized by severe microangiIt appears that endothelial cell injury is primarily opathic haemolytic anaemia and thrombocytopenia.
involved in the sequence of events leading to acute HUS is characterized by thrombocytopenia, anaemia episodes of HUS and TTP. and renal insufficiency, whereas the pentad of signs and symptoms including thrombocytopenia, anaemia, neurologic deficit, renal dysfunction and fever is Endothelial cell activation in HUS observed in TTP. However, about 60% of patients diagnosed with acute TTP lack one or more of these The majority of cases with HUS occur in the childhood criteria, while about 30% of those receiving a diagnosis and are preceded by bloody diarrhoea, usually caused of HUS exhibit neurologic symptoms and fever. Thus, by some strains of enterohaemorrhagic Escherichia coli the two disorders are often difficult to distinguish. or Shigella dysenteriae. It is generally held that in Given the lack of consistent clinical findings, the same diarrhoea-associated HUS (D+HUS ), activation of disorder might be diagnosed as HUS by a nephrologist endothelial cells with subsequent release of von while a haematologist might call it TTP. Since both Willebrand factor (vWF ) and increased endothelial HUS and TTP have been reported to occur in siblings secretion of plasminogen activator inhibitor I (PAI-1), and on different occasions even in the same patient, it is central to clumping of platelets in the renal microcirsometimes appears that the two disorders are different culation. Shiga-toxin receptors are most abundant in manifestations of the same pathophysiologic process. the proximal tubular cells. Shiga-toxin appears to The terms TTP/HUS, microangiopathic haemolytic produce tubular epithelial cell damage and to induce anaemia and thrombotic microangiopathy are some-tumour necrosis factor ( TNFa) in kidneys but not in times used to avoid an uncertain differential diagnosis. other organs [1] . HUS and TTP are characterized by disseminated micAtypical HUS, also denoted as sporadic HUS, is rothrombi composed of agglutinated platelets, that characterized by the absence of antecedent diarrhoea occlude arterioles and capillaries in the microcircul-(D−HUS), the tendency to relapse, a generally poor ation. In HUS the platelet microthrombi are primarily outcome, and often by a positive family history. confined to the kidneys, and thus renal failure is the Hypocomplementaemia and low complement C3 levels dominant feature. In TTP the microvascular occlusions have been observed in atypical HUS. Several cases of may occur in any tissue and lead to fluctuating familial HUS have been reported [2] [3] [4] [5] with deficiency ischaemic dysfunction of the respective organs, most of complement factor H, also denoted as b 1 H globulin. frequently of the brain, producing intermittent neuro-Factor H is a cofactor for the factor I-mediated logical symptoms. Markers of activated coagulation cleavage of the active form C3b of the complement are only mildly increased in contrast to disseminated factor C3. Factor H accelerates the decay of the C3 intravascular coagulation. No significant amounts of convertase and inhibits its formation. Low levels or fibrin are formed and rather low amounts of fibrin absence of factor H result in increased activation of degradation products are present. Blood clotting times the alternative complement pathway. In addition to (prothrombin time, activated partial thromboplastin abnormal factor H, abnormalities of other regulators time) are usually normal. The hypotheses concerning of the alternative pathway may also be implicated in the aetiology of HUS and TTP are controversial and the development of HUS. suggest that different pathogenetic mechanisms may trigger the disease. 13] . The protease inhibitor turned out to be an IgG. Prolonged treatment by plasma exchange and immune complexes), specific platelet agglutinating plasma proteins, release of a calcium-dependent pro-plasma infusion, corticosteroid and vincristine therapy resulted in disappearance of the inhibitor with transient tease (calpain) or of lysosomal cathepsin-like cysteine proteases, deficiency of prostacyclin, free radical appearance of the protease activity. In the further course of the disease, the platelet count again gradually formation, and abnormal processing of vWF multimers. vWF is a plasma glycoprotein composed of a decreased with concomitant reappearance of the inhibitor and disappearance of the vWF-cleaving protease variable number of 270 kD subunits linked by disulphide bonds. vWF multimers circulating in normal activity leading to several relapses of acute TTP.
Splenectomy, performed 1 year after the first TTP human plasma range in size between 500 and 20 000 kD. Unusually large vWF multimers are secreted from event, resulted in disappearance of the autoantibody and normalization of the protease activity, of the specific storage organelles ( Weibel-Palade bodies) of endothelial cells. These highly polymeric forms of vWF platelet count and haemoglobin levels.
A strong association of TTP with constitutional as may bind spontaneously to platelets at high levels of shear stress [6 ] and may agglutinate intact circulating well as with acquired deficiency of vWF-cleaving protease was subsequently confirmed in a retrospective platelets. Moake et al. [7] observed unusually large vWF multimers in plasma samples from patients with multi-centre study on the prevalence of protease deficiency in patients with familial or acquired TTP [14] . chronic relapsing forms of TTP. They tentatively predicted that in normal individuals a 'depolymerase' may Lacking or strongly decreased protease activity was found in all 30 examined patients with TTP (six familial be responsible for the conversion of unusually large vWF multimers to smaller polymers normally found and 24 non-familial cases) while no protease deficiency was found in 120 normal subjects. An inhibitor of in the circulation. This enzyme was proposed to be either a protease or a disulphide bond reductase redu-vWF-cleaving protease was established in 20 of the 24 patients with non-familial TTP but in none with familcing the size of the unusually large vWF multimers binding spontaneously to platelets thus giving rise to ial TTP. A deficiency of vWF-cleaving protease in patients with TTP was also reported by Tsai and Lian platelet thrombi within the microvasculature [7] . A specific protease that cleaves purified human vWF in [15] who found no activity in 39 plasma samples of 37 patients obtained during the acute TTP episode. IgG vitro to fragments produced by in vivo proteolysis has been recently purified from normal plasma [8, 9] . This antibodies with protease inhibitory activity were detected in two thirds of samples collected during the protease is different from all known proteases, is activated by divalent cations such as Ba2+ and less by acute event. No inhibitor was found in 16 plasma samples obtained during a remission of TTP. Normal protease activity was found in 21 of 23 patients with HUS (10 familial and 13 non-familial cases) [14] . Nevertheless, unusually large multimers of vWF have
Deficiency of von Willebrand factor-cleaving
also been observed in plasma samples of patients with protease in TTP HUS [16 ] . We have excluded a resistance of the vWF in the plasma of these patients against proteolytic degradation by vWF-cleaving protease [14] . It is conAn abnormal degradation of vWF has been recently established in two brothers with chronic relapsing TTP ceivable that in an acute event of HUS, the local intense stimulation or damage of renal endothelial cells who showed unusually large vWF multimers in their plasma [11] . Both patients had complete deficiency of leads to massive release of very large vWF multimers that escape proteolytic degradation and agglutinate vWF-cleaving protease activity, whereas their parents had about half normal protease activity, and the sister platelets in the microcirculation of the kidney.
The difference between TTP and HUS permits a had normal activity, suggesting that the deficiency of the vWF-cleaving protease may be inherited in an differential diagnosis of these two similar disorders that are often difficult to distinguish clinically. In autosomal recessive manner. No inhibitor of the protease activity was found in the patients' plasma [11] . addition, the assay of protease inhibitor may provide useful information regarding the prognosis and therapy The recovery of vWF-cleaving protease following plasma exchange and replacement of fresh frozen of patients with TTP. Two new functional assays of vWF-cleaving protease have been recently described: plasma (FFP) in both patients with constitutional protease deficiency was about 100% and its biologic one method is based on decreased binding of degraded vWF to collagen-coated microtiter plates [17] , while half-life was 2-4 days [12] .
The lack of vWF-cleaving protease activity in the other method consists of a two-site immunoradio-
